PLK1 inhibitors, in combination with chemotherapy, have shown enhanced anti-cancer efficacy both in vitro and in vivo by leveraging complementary mechanisms, leading to stronger tumor suppression [39]. The gene discussed is PLK1; the disease is neoplasm.